Anti-PVRIG/TIGIT Bispecific Antibody Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations lack high-avidity, high-selectivity, and high-bioactivity anti-PVRIG/TIGIT bispecific antibodies capable of effectively inhibiting cancer or tumor growth in vivo.
Innovation Solution
A pharmaceutical composition comprising an anti-PVRIG/TIGIT bispecific antibody with specific antigen-binding domains and a buffer system, including histidine or acetate buffers, to maintain stability and efficacy, along with a surfactant and osmotic pressure regulator, is developed to enhance therapeutic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations are used, then general stability is maintained, but high-avidity, high-selectivity, and high-bioactivity are not achieved
Solution Approach 1:
The patent optimizes specific formulation parameters including pH (5.0-7.5), buffer concentration (5-50 mM), surfactant concentration (0.01-1%), and osmotic pressure (200-400 mOsm) to achieve high bioactivity while maintaining formulation simplicity. These parameter optimizations enable the anti-PVRIG/TIGIT bispecific antibody to achieve high-avidity and high-selectivity without requiring complex formulation systems.
2Stability of the object's composition
If buffer system is added to maintain stability, then pH control is improved, but formulation complexity increases
Solution Approach 1:
The patent specifies optimal pH ranges (5.0-7.5) and buffer concentrations (5-50 mM) to achieve adequate pH stability without requiring complex buffer systems. This parameter optimization provides sufficient pH control while maintaining formulation simplicity.
Solution Approach 2:
The patent employs simple, commonly available buffer systems (histidine, acetate, or phosphate buffers) that are easy to prepare and maintain stability during storage and administration, avoiding the need for complex or specialized buffering systems.
3Reliability
If surfactant and osmotic pressure regulator are added, then therapeutic activity is enhanced, but formulation complexity increases
Solution Approach 1:
The patent optimizes surfactant concentrations (0.01-1%) and osmotic pressure (200-400 mOsm) to achieve enhanced therapeutic activity while maintaining formulation simplicity. These parameter ranges provide adequate stabilization and therapeutic effect without requiring complex formulation systems.
Solution Approach 2:
The patent employs common, readily available excipients including surfactants (polysorbate 20, polysorbate 80, poloxamer 188) and osmotic pressure regulators (sucrose, glucose, sodium chloride) that are easy to source and incorporate, avoiding the need for specialized or complex stabilization systems.
Data Source
AI summary
A pharmaceutical composition comprising an anti-PVRIG/TIGIT bispecific antibody.